Elizabeth Livingston

Dr. Elizabeth Livingston

orcid

Research Focus & Metrics

Academic Career Length

48Years (1979-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Obstetrical & Gynecological Survey
Verified
Journal Article
Closed access
PDF file
AWAmber M. Wood
Amber M. Wood
ELElizabeth Livingston
Elizabeth Livingston
BHBrenna L. Hughes
Brenna L. Hughes
JKJeffrey A. Kuller
Jeffrey A. Kuller
Importance: Intrahepatic cholestasis of pregnancy (ICP) complicates approximately 0.2% to 2% of pregnancies and can lead to increased fetal risks in pregnancy. Objective: This review aims to increase the knowledge of women's health care providers regarding the diagnosis, management, and fetal risks associated with ICP. Results: The diagnosis of ICP is based on symptoms of pruritus that typically include the palms and soles, as well as elevated bile acid levels. Other liver function tests such as alanine aminotransferase and aspartate aminotransferase are also frequently elevated, and other causes of liver dysfunction should be ruled out. Fetal risks of ICP include increased risk of preterm birth, meconium-stained amniotic fluid, respiratory distress syndrome, or stillbirth. There is evidence that as bile acid levels increase, so does the risk of adverse neonatal outcomes. Ursodeoxycholic acid treatment has been shown to improve maternal pruritus symptoms, as well as biochemical tests, but no treatment has been shown to definitively improve fetal outcomes. Conclusions and Relevance: Providers should be aware of the signs and symptoms of ICP and provide accurate diagnosis and management of affected women. Women with a diagnosis of ICP should be treated with ursodeoxycholic acid to improve maternal symptoms. Given the increased risk of stillbirth in the setting of ICP, delivery may be considered at 37 weeks' gestation. Target Audience: Obstetricians and gynecologists, family physicians. Learning Objectives: After completing this activity, the learner should be better able to identify symptoms of and diagnose ICP, counsel patients on neonatal risks associated with the diagnosis of ICP, and provide treatment for women with a diagnosis of ICP.

1 April 2010 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
KPKunjal Patel
Kunjal Patel
DSDavid E. Shapiro
David E. Shapiro
SBSusan B. Brogly
Susan B. Brogly
ELElizabeth Livingston
Elizabeth Livingston
ASAlice M. Stek
Alice M. Stek
RTRuth E. Tuomala
Ruth E. Tuomala
Background. Conflicting results have been reported among studies of protease inhibitor (PI) use during pregnancy and preterm birth. Uncontrolled conf

1 June 1990 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
JPJ.T. Parer
J.T. Parer
ELElizabeth Livingston
Elizabeth Livingston

26 March 1992 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
RSRhoda S. Sperling
Rhoda S. Sperling
PSPamela Stratton
Pamela Stratton
MOMary Jo O'SUllivan
Mary Jo O'SUllivan
PBPamela Boyer
Pamela Boyer
DWD. Heather Watts
D. Heather Watts
HFHarold E. Fox
Harold E. Fox
The expanding indications for zidovudine treatment make it important to elucidate the safety and toxicity of this drug for pregnant women and their fetuses. We asked pediatricians and obstetricians at the AIDS (acquired immunodeficiency syndrome) Clinical Trials Units to report information about pregnant women infected with the human immunodeficiency virus who were continuing their pregnancies and had received, or were receiving, zidovudine during gestation.

19 March 2007 in Environmental and Molecular Mutagenesis
Verified
Journal Article
Closed access
PDF file
KWKristine L. Witt
Kristine L. Witt
CCColeen K. Cunningham
Coleen K. Cunningham
KPKristine B. Patterson
Kristine B. Patterson
GKGrace E. Kissling
Grace E. Kissling
SDStephen D. Dertinger
Stephen D. Dertinger
JBJack B. Bishop
Jack B. Bishop

1 December 2013 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
CRCarla E. Ransom
Carla E. Ransom
YHYanling Huo
Yanling Huo
KPKunjal Patel
Kunjal Patel
GSGwendolyn B. Scott
Gwendolyn B. Scott
HWHeather D. Watts
Heather D. Watts
ELElizabeth Livingston
Elizabeth Livingston
Objective: To determine whether maternal use of tenofovir disoproxil fumarate for treatment of HIV in pregnancy predicts fetal and infant growth. Methods: The study population included HIV-uninfected live-born singleton infants of mothers enrolled in the International Maternal Pediatric Adolescent AIDS Clinical Trials Group protocol P1025 (born 2002–2011) in the United States and exposed in utero to a combined (triple or more) antiretroviral regimen. Infant weight at birth and 6 months was compared between infants exposed and unexposed to tenofovir in utero using 2-sample t test, χ2 test, and multivariable linear and logistic regression models, including demographic and maternal characteristics. Results: Among 2025 infants with measured birth weight, there was no difference between those exposed (N = 630, 31%) versus unexposed to tenofovir in mean birth weight (2.75 vs. 2.77 kg, P = 0.64) or mean gestational age- and sex-adjusted birth weight z-score (WASZ) (0.14 vs. 0.14, P = 0.90). Among 1496 infants followed for 6 months, there was no difference in mean weight at 6 months between tenofovir-exposed (N = 457, 31%) and tenofovir-unexposed infants (7.64 vs. 7.59 kg, P = 0.52) or in mean WASZ (0.29 vs. 0.26, P = 0.61). Tenofovir exposure during the second/third trimester, relative to no exposure, significantly predicted underweight (WASZ < 5%) at age 6 months [odds ratio (95% confidence interval): 2.06 (1.01 to 3.95), P = 0.04]. Duration of tenofovir exposure did not predict neonatal or infant growth. Conclusions: By most measures, in utero exposure to tenofovir did not significantly predict infant birth weight or growth through 6 months of age.